|
1
|
van der Graaf WT, Orbach D, Judson IR and
Ferrari A: Soft tissue sarcomas in adolescents and young adults: A
comparison with their paediatric and adult counterparts. Lancet
Oncol. 18:e166–e175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kager L, Tamamyan G and Bielack S: Novel
insights and therapeutic interventions for pediatric osteosarcoma.
Future Oncol. 13:357–368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weiss A, Gill J, Goldberg J, Lagmay J,
Spraker-Perlman H, Venkatramani R and Reed D: Advances in therapy
for pediatric sarcomas. Curr Oncol Rep. 16:3952014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dela Cruz FS: Cancer stem cells in
pediatric sarcomas. Front Oncol. 3:1682013.PubMed/NCBI
|
|
6
|
Gibbs CP, Kukekov VG, Reith JD,
Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN and
Steindler DA: Stem-like cells in bone sarcomas: Implications for
tumorigenesis. Neoplasia. 7:967–976. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsuchida R, Das B, Yeger H, Koren G,
Shibuya M, Thorner PS, Baruchel S and Malkin D: Cisplatin treatment
increases survival and expansion of a highly tumorigenic
side-population fraction by upregulating VEGF/Flt1 autocrine
signaling. Oncogene. 27:3923–3934. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Fiore R, Santulli A, Ferrante RD,
Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere
G and Vento R: Identification and expansion of human
osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide
treatment. J Cell Physiol. 219:301–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tirino V, Desiderio V, D'Aquino R, de
Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, de
Rosa A, Papaccio G, et al: Detection and characterization of CD133+
cancer stem cells in human solid tumours. PLoS One. 3:e34692008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Veselska R, Kuglik P, Cejpek P, Svachova
H, Neradil J, Loja T and Relichova J: Nestin expression in the cell
lines derived from glioblastoma multiforme. BMC Cancer. 6:322006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone
sarcomas contain CD133+ cancer stem cells displaying high
tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang M, Yan M, Zhang R, Li J and Luo Z:
Side population cells isolated from human osteosarcoma are enriched
with tumor-initiating cells. Cancer Sci. 102:1774–1781. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adhikari AS, Agarwal N, Wood BM, Porretta
C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify
osteosarcoma tumor-initiating cells associated with metastasis and
drug resistance. Cancer Res. 70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Penfornis P, Cai DZ, Harris MR, Walker R,
Licini D, Fernandes JD, Orr G, Koganti T, Hicks C, Induru S, et al:
High CD49f expression is associated with osteosarcoma tumor
progression: A study using patient-derived primary cell cultures.
Cancer Med. 3:796–811. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ying M, Liu G, Shimada H, Ding W, May WA,
He Q, Adams GB and Wu L: Human osteosarcoma CD49f(−)CD133(+) cells:
Impaired in osteogenic fate while gain of tumorigenicity. Oncogene.
32:4252–4263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wilkens S: Structure and mechanism of ABC
transporters. F1000 Prime Rep. 7:142015. View Article : Google Scholar
|
|
17
|
Martins-Neves SR, Paiva-Oliveira DI,
Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovée JV,
Cleton-Jansen AM and Gomes CM: Chemotherapy induces stemness in
osteosarcoma cells through activation of Wnt/β-catenin signaling.
Cancer Lett. 370:286–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martins-Neves SR, Corver WE,
Paiva-Oliveira DI, Van Den Akker BE, Briaire-de-Bruijn IH, Bovee
JV, Gomes CM and Cleton-Jansen AM: Osteosarcoma stem cells have
active Wnt/beta-catenin and Overexpress SOX2 and KLF4. J Cell
Physiol. 231:876–886. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Park P, Zhang H, La Marca F and
Lin CY: Prospective identification of tumorigenic osteosarcoma
cancer stem cells in OS99-1 cells based on high aldehyde
dehydrogenase activity. Int J Cancer. 128:294–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Greco N, Schott T, Mu X, Rothenberg A,
Voigt C, McGough RL III, Goodman M, Huard J and Weiss KR: ALDH
Activity correlates with metastatic potential in primary sarcomas
of bone. J Cancer Ther. 5:331–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weina K and Utikal J: SOX2 and cancer:
Current research and its implications in the clinic. Clin Transl
Med. 3:192014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang C, Hou C, Zhang H, Wang D, Ma Y,
Zhang Y, Xu X, Bi Z and Geng S: miR-126 functions as a tumor
suppressor in osteosarcoma by targeting Sox2. Int J Mol Sci.
15:423–437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Basu-Roy U, Bayin NS, Rattanakorn K, Han
E, Placantonakis DG, Mansukhani A and Basilico C: Sox2 antagonizes
the Hippo pathway to maintain stemness in cancer cells. Nat Commun.
6:64112015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balamuth NJ and Womer RB: Ewing's sarcoma.
Lancet Oncol. 11:184–192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kinsey M, Smith R, Iyer AK, McCabe ER and
Lessnick SL: EWS/FLI and its downstream target NR0B1 interact
directly to modulate transcription and oncogenesis in Ewing's
sarcoma. Cancer Res. 69:9047–9055. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tirode F, Laud-Duval K, Prieur A, Delorme
B, Charbord P and Delattre O: Mesenchymal stem cell features of
Ewing tumors. Cancer Cell. 11:421–429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Karski EE, McIlvaine E, Segal MR, Krailo
M, Grier HE, Granowetter L, Womer RB, Meyers PA, Felgenhauer J,
Marina N, et al: Identification of discrete prognostic groups in
Ewing sarcoma. Pediatr Blood Cancer. 63:47–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suvà ML, Riggi N, Stehle JC, Baumer K,
Tercier S, Joseph JM, Suvà D, Clément V, Provero P, Cironi L, et
al: Identification of cancer stem cells in Ewing's sarcoma. Cancer
Res. 69:1776–1781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riggi N, Suvà ML, De Vito C, Provero P,
Stehle JC, Baumer K, Cironi L, Janiszewska M, Petricevic T, Suvà D,
et al: EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate
mesenchymal stem cell reprogramming toward Ewing sarcoma cancer
stem cells. Genes Dev. 24:916–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu N, Papagiannakopoulos T, Pan G, Thomson
JA and Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and
represses pluripotency in human embryonic stem cells. Cell.
137:647–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barta T, Peskova L, Collin J, Montaner D,
Neganova I, Armstrong L and Lako M: Brief Report: Inhibition of
miR-145 enhances reprogramming of human dermal fibroblasts to
induced pluripotent stem cells. Stem Cells. 34:246–251. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Panza A, Votino C, Gentile A, Valvano MR,
Colangelo T, Pancione M, Micale L, Merla G, Andriulli A, Sabatino
L, et al: Peroxisome proliferator-activated receptor γ-mediated
induction of microRNA-145 opposes tumor phenotype in colorectal
cancer. Biochim Biophys Acta. 1843:1225–1236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wahl J, Bogatyreva L, Boukamp P, Rojewski
M, van Valen F, Fiedler J, Hipp N, Debatin KM and Beltinger C:
Ewing's sarcoma cells with CD57-associated increase of
tumorigenicity and with neural crest-like differentiation capacity.
Int J Cancer. 127:1295–1307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leuchte K, Altvater B, Hoffschlag S,
Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J, Dirksen U,
Juergens H, et al: Anchorage-independent growth of Ewing sarcoma
cells under serum-free conditions is not associated with stem-cell
like phenotype and function. Oncol Rep. 32:845–852. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scannell CA, Pedersen EA, Mosher JT, Krook
MA, Nicholls LA, Wilky BA, Loeb DM and Lawlor ER: LGR5 is expressed
by Ewing sarcoma and potentiates Wnt/β-catenin signaling. Front
Oncol. 3:812013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leushacke M and Barker N: Lgr5 and Lgr6 as
markers to study adult stem cell roles in self-renewal and cancer.
Oncogene. 31:3009–3022. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Takimoto T and Fujimoto J:
Prognostic model for predicting overall survival in children and
adolescents with rhabdomyosarcoma. BMC Cancer. 14:6542014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marshall AD and Grosveld GC: Alveolar
rhabdomyosarcoma - the molecular drivers of PAX3/7-FOXO1-induced
tumorigenesis. Skelet Muscle. 2:252012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ren YX, Finckenstein FG, Abdueva DA,
Shahbazian V, Chung B, Weinberg KI, Triche TJ, Shimada H and
Anderson MJ: Mouse mesenchymal stem cells expressing PAX-FKHR form
alveolar rhabdomyosarcomas by cooperating with secondary mutations.
Cancer Res. 68:6587–6597. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rubin BP, Nishijo K, Chen HI, Yi X,
Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR,
et al: Evidence for an unanticipated relationship between
undifferentiated pleomorphic sarcoma and embryonal
rhabdomyosarcoma. Cancer Cell. 19:177–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pressey JG, Haas MC, Pressey CS, Kelly VM,
Parker JN, Gillespie GY and Friedman GK: CD133 marks a myogenically
primitive subpopulation in rhabdomyosarcoma cell lines that are
relatively chemoresistant but sensitive to mutant HSV. Pediatr
Blood Cancer. 60:45–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hirotsu M, Setoguchi T, Matsunoshita Y,
Sasaki H, Nagao H, Gao H, Sugimura K and Komiya S: Tumour formation
by single fibroblast growth factor receptor 3-positive
rhabdomyosarcoma-initiating cells. Br J Cancer. 101:2030–2037.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nakahata K, Uehara S, Nishikawa S, Kawatsu
M, Zenitani M, Oue T and Okuyama H: Aldehyde dehydrogenase 1
(ALDH1) is a potential marker for cancer stem cells in embryonal
rhabdomyosarcoma. PLoS One. 10:e01254542015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Thomas RM, Kim J, Revelo-Penafiel MP,
Angel R, Dawson DW and Lowy AM: The chemokine receptor CXCR4 is
expressed in pancreatic intraepithelial neoplasia. Gut.
57:1555–1560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Krieg A, Riemer JC, Telan LA, Gabbert HE
and Knoefel WT: CXCR4− A prognostic and
clinicopathological biomarker for pancreatic ductal adenocarcinoma:
A meta-analysis. PLoS One. 10:e01301922015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shen B, Zheng MQ, Lu JW, Jiang Q, Wang TH
and Huang XE: CXCL12− CXCR4 promotes proliferation and
invasion of pancreatic cancer cells. Asian Pac J Cancer Prev.
14:5403–5408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Immervoll H, Hoem D, Steffensen OJ,
Miletic H and Molven A: Visualization of CD44 and CD133 in normal
pancreas and pancreatic ductal adenocarcinomas: Non-overlapping
membrane expression in cell populations positive for both markers.
J Histochem Cytochem. 59:441–455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hou YC, Chao YJ, Tung HL, Wang HC and Shan
YS: Coexpression of CD44-positive/CD133-positive cancer stem cells
and CD204-positive tumor-associated macrophages is a predictor of
survival in pancreatic ductal adenocarcinoma. Cancer.
120:2766–2777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li X, Zhao H, Gu J and Zheng L: Prognostic
value of cancer stem cell marker CD133 expression in pancreatic
ductal adenocarcinoma (PDAC): A systematic review and
meta-analysis. Int J Clin Exp Pathol. 8:12084–12092.
2015.PubMed/NCBI
|
|
52
|
Singh S, Arcaroli JJ, Orlicky DJ, Chen Y,
Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Thompson DC and
Vasiliou V: Aldehyde dehydrogenase 1B1 as a modulator of pancreatic
adenocarcinoma. Pancreas. 45:117–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
